sunitinib — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

sunitinib appears in hypotheses across 6 disease domains: Alzheimer, Epilepsy, Glioblastoma, Inflammatory bowel disease, Pancreatic cancer, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: STAT3.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for sunitinib

Alzheimer 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
STAT3	cognitive deficits	0.208	Mid	partial evidence	none

Epilepsy 4

Mediator	Outcome	Score	Tier	Lit. status	Trial
STAT3	imprinting of epileptic activity patterns	0.208	Mid	novel signal	none
STAT3	persistence of reactive glial states	0.208	Mid	novel signal	none
STAT3	general cell loss	0.208	Mid	novel signal	none
STAT3	GABAergic neuron loss	0.208	Mid	novel signal	none

Glioblastoma 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
angiogenesis	glioblastoma	0.269	Mid	reproduces known	completed
STAT3	glioblastoma progression	0.208	Mid	novel signal	none

Inflammatory bowel disease 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
STAT3	DSS-induced colitis	0.208	Mid	novel signal	none
STAT3	ulcerative colitis carcinogenesis	0.208	Mid	novel signal	none

Pancreatic cancer 3

Mediator	Outcome	Score	Tier	Lit. status	Trial
STAT3	drug resistance	0.208	Mid	reproduces known	none
STAT3	pancreatic ductal adenocarcinoma	0.208	Mid	reproduces known	none
STAT3	immune escape	0.208	Mid	reproduces known	none

Rheumatoid arthritis 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
STAT3	prurigo nodularis	0.312	High	novel signal	none

← All drugs